ADCETRIS

Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Marketed
Partnering status

Partnered
Partner

Takeda Pharmaceutical Company Limited.
Available in

EU, US, LATAM, JAPAC, Switzerland

You may also be interested in

F2i

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Discovery

MV-002

MV-002 is an orally available modified live biotherapeutic converting the majority of solid tumor patients refractory to immune checkpoint blockade (ICB) to responders. MV002 in combination with different ICB significantly increases the percentage of responding animals (e.g. anti-PD-L1 monotherapy, from 25-30% to 70/80% with MV-002 in translational models of solid tumor).

Discovery

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx

4D Lifetest Lung Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of lung cancer for symptomatic patients in combination with other lung cancer specific diagnostics. 4D Lifetest Breast Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of breast cancer for symptomatic patients in combination with other breat cancer specific diagnostics. 4D Lifetest Colon Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of colon cancer for symptomatic patients in combination with other colon cancer specific diagnostics.

Marketed